EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies

Shaza Hammad, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02559-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Shaza Hammad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon. Hauptthemen laut MEDLINE: Antibodies, Bispecific, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advancements in cancer immunotherapy have spotlighted the PD-1/PD-L1 pathway, crucial for its role in immune checkpoint regulation. Traditional inhibitors, though successful, face challenges like resistance and adverse effects. Bispecific antibodies targeting PD-1 and PD-L1 present a ground-breaking solution by simultaneously engaging multiple immune regulatory molecules. Developments in PD-1/PD-L1 bispecific antibodies up to now have been summarized, and the latest findings from the 2024 ASCO conference are presented, revealing that bispecific antibodies exhibit robust efficacy in treating various types of cancers, marking a significant step forward in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificB7-H1 AntigenProgrammed Cell Death 1 ReceptorNeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapy

Stichwörter der Autor:innen

Bispecific antibodiesCancer immunotherapyImmune checkpoint regulationPD-1 inhibitorsPD-1/PD-L1 pathwayPD-L1 inhibitors

Substanzen

Antibodies, BispecificB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.
  • Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon. boutrosmarc2001@gmail.com.
  • Department of Hematology-Oncology, Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.

Zitieren

APA

Hammad, S., Boutros, M., Attieh, F., & Kourie, H. R. (2024). Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies. Medical Oncology. https://doi.org/10.1007/s12032-024-02559-3

Vancouver

Hammad S, Boutros M, Attieh F, Kourie HR. Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies. Medical Oncology. 2024. doi:10.1007/s12032-024-02559-3

BibTeX
@article{Hammad2024,
  author = {Hammad, Shaza and Boutros, Marc and Attieh, Fouad and Kourie, Hampig Raphaël},
  title = {Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02559-3}
}
Kostenlos starten →